#14: TheMachine: Accentia Biopharmaceuticals to Announce Top-Line SinuNase Phase 3 Clinical Trial Results Later Today
CEO Conference Call/Webcast Scheduled for 5:00 p.m. (EDT)
... |
April 4, 2008
01:46:13 AM |
#13: Stock News Bot: Accentia Biopharmaceuticals Reports Fiscal 2007 Year-End Results; Pivotal Phase III Results Pending for SinuNase(TM) and BiovaxID(TM)
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that the
... |
December 29, 2007
08:09:22 AM |
#12: Stock News Bot: Biovest Announces It Has Closed an $8.5M Financing to Support Unblinding and Data Analysis of Fast Tracked Pivotal Phase 3 Study of BiovaxID for Non-Hodgkin's Lymphoma with Public Release of Results Anticipated by April 2008
Biovest Announces It Has Closed an $8.5M Financing to Support Unblinding and Data... |
December 11, 2007
01:53:46 PM |
#11: Stock News Bot: BVTI News U.S. Bank, State of Missouri, and City of St. Louis Partner With Biovest International to Provide Second Round of New Market Tax Credits
WORCESTER, Mass. & ST. LOUIS--(BUSINESS WIRE)--U.S. Bank, the State of Missouri... |
December 18, 2006
06:47:00 AM |
#10: Stock News Bot: BVTI News Biovest International Launches Breakthrough Cell Culture Instrument
WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB:BVTI)... |
November 1, 2006
11:19:00 AM |
#9: Stock News Bot: BVTI News Biovest International's Phase 3 Therapy for Follicular Lymphoma Receives Independent Support From Newly Published Phase 2 Trial Data
WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB: BVTI)... |
October 19, 2006
05:30:00 AM |
#8: Stock News Bot: BVTI News Biovest International Therapy for Follicular Non-Hodgkin's Lymphoma Receives Rare Disease Designation from European Drug Agency
WORCESTER, Mass.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB: BVTI) ... |
October 11, 2006
05:30:00 AM |
#7: Stock News Bot: BVTI News Biovest International Receives Positive Opinion on Application for Orphan Medicinal Product Designation by European Agency; Opinion expected to aid approval of BiovaxID(TM) in the EU
WORCESTER, Mass.--(BUSINESS WIRE)--July 31, 2006--Biovest International, Inc.... |
July 31, 2006
06:07:00 AM |
#6: Stock News Bot: BVTI News Biovest International Appoints New Senior Advisor; New Addition Strengthens Management's Medical Expertise
WORCESTER, Mass.--(BUSINESS WIRE)--July 26, 2006--Biovest International, Inc.... |
July 26, 2006
09:57:00 AM |
#5: Stock News Bot: BVTI News Biovest International Gains Key Regulatory Approval for Clinical Trial Sites in Russia; Biovest to open 14 new clinical sites, accelerating patient recruitment
WORCESTER, Mass.--(BUSINESS WIRE)--July 18, 2006--Biovest International, Inc.... |
July 18, 2006
06:16:00 AM |
#4: Stock News Bot: BVTI News Accentia Biopharmaceuticals Announces Option Agreement with Mayo on Patented Treatment Using Intranasal Antifungals for Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 15, 2005--Accentia Biopharmaceuticals, Inc.... |
December 15, 2005
03:25:00 AM |
#2: Stock News Bot: BVTI News AutovaxID(TM)-C Introduced by Biovest International; Automated Instrumentation Marks Major Breakthrough for Vaccine Production and Personalized Medicine
WORCESTER, Mass.--(BUSINESS WIRE)--Dec. 8, 2005--Biovest International, Inc.... |
December 8, 2005
03:27:00 AM |
#3: Stock News Bot: BVTI News AutovaxID(TM)-C Introduced by Accentia Biopharmaceuticals; Automated Instrumentation Marks Major Breakthrough for Vaccine Production and Personalized Medicine
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 8, 2005--Accentia Biopharmaceuticals, Inc.... |
December 8, 2005
03:27:00 AM |
#1: Stock News Bot: BVTI News Accentia Biopharmaceuticals Acquires Exclusive License for an Additional Late-Stage Respiratory Product
TAMPA, Fla.--(BUSINESS WIRE)--Dec. 6, 2005--Accentia Biopharmaceuticals, Inc.... |
December 6, 2005
03:27:00 AM |
